Gene expression

Subtype-specific transcriptional regulators in breast tumors subjected to genetic and epigenetic alterations

Qian Zhu\(^1\), Xavier Tekpli\(^2,3\), Olga G. Troyanskaya\(^4,5,6,*,†\) and Vessela N. Kristensen\(^2,3,7,*,†\)

\(^1\)Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA, \(^2\)Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway, \(^3\)Division of Medicine, Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway, \(^4\)Department of Computer Science and Lewis-Sigler Institute of Integrative Genomics, Princeton University, Princeton, NJ 08540, USA, \(^5\)Simons Foundation, Flatiron Institute, New York, NY 10010, USA and \(^7\)Institute for Clinical Medicine, University of Oslo, Oslo, Norway

*To whom correspondence should be addressed.
†The authors wish it to be known that, in their opinion, the last two authors should be regarded as Joint Last Authors.
Associate Editor: Russell Schwartz

Received on February 21, 2019; revised on September 4, 2019; editorial decision on September 6, 2019; accepted on September 12, 2019

Abstract

Motivation: Breast cancer consists of multiple distinct tumor subtypes, and results from epigenetic and genetic aberrations that give rise to distinct transcriptional profiles. Despite previous efforts to understand transcriptional deregulation through transcription factor networks, the transcriptional mechanisms leading to subtypes of the disease remain poorly understood.

Results: We used a sophisticated computational search of thousands of expression datasets to define extended signatures of distinct breast cancer subtypes. Using ENCODE ChIP-seq data of surrogate cell lines and motif analysis we observed that these subtypes are determined by a distinct repertoire of lineage-specific transcription factors. Furthermore, specific pattern and abundance of copy number and DNA methylation changes at these TFs and targets, compared to other genes and to normal cells were observed. Overall, distinct transcriptional profiles are linked to genetic and epigenetic alterations at lineage-specific transcriptional regulators in breast cancer subtypes.

Availability and implementation: The analysis code and data are deposited at https://bitbucket.org/qzhu/breast.cancer.tf/. Contact: ogt@genomics.princeton.edu or v.n.kristensen@medisin.uio.no

Supplementary information: Supplementary data are available at Bioinformatics online.

1 Introduction

Tumorigenesis in breast cancer is thought to be the result of a combination of somatic genetic events including copy number alterations (CNA), point mutations and epigenetic alterations such as DNA methylation (DNAme). In contrast to normal tissue development, in tumors somatic mutations accumulate at various points of the differentiation process, making normal cells acquire properties of stem cells that turn them into cancer cells. Despite the extensive generation of molecular data, how these mutations and aberrations specifically affect transcription factors and their targets is not well understood.

Breast cancer is a heterogeneous disease comprised of several molecular subtypes: luminal A, luminal B, Her2, basal-like and normal-like (Hu et al., 2006; Perou et al., 2000; Sorlie and Perou, 2001). Of these, luminal A and basal-like (hitherto referred to as basal) are the most extreme in terms of spanning the prognosis and treatment decision spectrum, with luminal A being ‘best’ prognosis and basal being the worst. Aberrations in breast cancer are manifested in a subtype-specific manner, and distinct biological processes are uniquely perturbed in these subtypes (Curtis et al., 2012; Nik-Zainal et al., 2012). Previous efforts have identified mutational events at an unprecedented resolution and scale, linking those to the breast cancer subtypes (Cancer and Atlas, 2012). Because of the distinct expression profiles, it is thought that the development of cancer involves the combinatorial effects of transcription factors expressed in a coordinated manner. Together they evolve downstream of germ-line and somatic genetic events and subtype-specific regulators can further give rise to the subtype-specific co-expression of downstream target genes.

To study the regulatory effect on transcription, various TF regulatory networks have been constructed from ChIP-seq and ChIP-ChIP data, including a general TF network created by the ENCODE project (Dunham et al., 2012; Gerstein et al., 2012; Kundaje et al., 2015), and for breast—a nuclear receptor TF network focused on MCF7 cells (Kittler et al., 2013). Computational efforts have
identified master regulators from differentially expressed and coexpressed genes (Janky et al., 2014), or from motifs overrepresented in promoter regions (Joshi et al., 2012; Tongbai et al., 2008). Some identified transcriptional differences in normal breast development through histone marks (Pellacani et al., 2016). These previous analyses described a general disease network and have not been breast cancer subtype-specific. Given that subtypes are strongly linked to clinical outcome, subtype-specific regulatory networks need to be identified and effects of genetic and epigenetic aberrations on transcriptional regulators need to be studied further.

To toward this goal, we integrate breast cancer subtype-specific transcriptomic and cistromic (ChiP-seq) datasets to infer regulators and targets underlying breast cancer subtypes. We used 152 breast cancer gene expression datasets adding to a total of 10280 samples, including TCGA (Cancer and Atlas, 2012), METABRIC (Curtis et al., 2012) and patient cohort studies, including one by us (Aure et al., 2013), produced on diverse microarray and RNA-seq platforms, to define subtype-specific genes with a computational search-based algorithm (Zhao et al., 2015). Then relevant regulators of each subtype were identified through the enrichment of two evidence at each subtype’s coexpressed genes: transcription factor (TF) binding evidence from ENCODE ChiP-seq database (Dunham et al., 2012), and motif enrichment evidence within regulatory regions (including TF binding sites and open chromatin regions). Particularly, we found a set of ChiP’d TFs from ENCODE whose binding sites were commonly enriched for loci near coexpressed genes that were upregulated in each subtype, implying that the binding of these TFs is associated in large part with coexpression. Most importantly, we, for the first time, identify a subtype-specific tendency for the mechanism of de-regulation of transcription factors via DNA hypo/hyper methylation in the best prognosis luminal A, or somatic copy number aberrations in the worst prognosis basal subtype. Furthermore, by the integration of ChiP-seq data with expanded coexpressed gene signatures we derive direct evidence of epithelial-mesenchymal transition (EMT), and embryonic stemness in the basal subtype, identifying that target genes are decomposed into those belonging to one, or the other cell lineage, or shared by both lineages (epithelial and stem cell). Finally, based on this analysis we identify two more cell lines, A549 and H1-hESc, as associated to the basal subtype in addition to the known oncogenic MCF10A-Er-Src cell line.

2 Materials and methods

To understand how transcriptional events influence the development of breast cancer cells, we reverse engineer the process, starting with coexpressed genes in each luminal A and basal subtype. We used our computational search algorithm SEEK (Zhu et al., 2015) applied to 152 breast cancer datasets (Supplementary Data S1) to accurately identify subtype-specific gene signatures (ESG) (Supplementary Table S1 and Supplementary Data S2) based on the smaller seed lists of published subtype-specific genes (Muggerud et al., 2006) (Supplementary Table S1). The ESGs were verified to be differentially expressed between subtypes in the external METABRIC cohort (Supplementary Tables S2 and S3).

ChiP-seq data processing: We used the collection of ChiP-seq datasets processed by the ENCODE Analysis Working Group. To derive a gene score representing the amount of binding per gene, we first divide the peak signal score (the number of tags) by the 75 percentile peak score of the whole experiment, multiplied by base score 500. Next the peaks’ chromosomal locations are aligned to all the regulatory regions (50 kb ± TSS) of ESGs are significantly higher than binding at random sets of genes. If significance is reached, then ChiP’d TFs are termed regulators of the subtype.

Motif and coexpression based evidence: We performed motif analyses within peaks of ChiP-seq experiments in relevant cell lines to search for any motifs that might be enriched, as described previously (Machanick and Bailey, 2011). We additionally required that the TF identified via this analysis must be coexpressed to the target genes, to be considered as a regulator (as a motif often encompasses a family of TFs).

See Supplementary Figure S1 for a workflow of our analyses.

To reveal associations between identified TFs and CNA or DNAme, we obtained relevant datasets from the breast cancer cohort in TCGA (Cancer and Atlas, 2012) and two other independent datasets, METABRIC and OSLO2 (Curtis et al., 2012; Fleischer et al., 2014).

DNA methylation (DNAme) processing: TCGA array-based DNAme dataset was downloaded from ICGC in nucleotide-resolution methylation frequencies (beta values). We excluded blood-derived normal samples, and metastatic samples from the TCGA list. We used primary tumor samples and also obtained a separate normal breast tissue sample set from TCGA for comparison. To start, nucleotide-resolution beta values per patient sample was summed to gene-level values. Then, to derive subtype-specific hyper- and hypo-methylated genes, for every gene, we compared the distribution of methylation frequency of subtype patient group and that of the healthy group consisting of normal breast tissue samples, by performing 2-sample t-tests with unequal variance with respect to the normal sample group. Genes with P < 0.01 significance are deemed hyper or hypo-methylated respectively.

Copy number alteration (CNA) processing: For CNA (Curtis et al and TCGA), original data consists of copy number for various chromosomal segments detected per patient. Each copy number ranges from -1 to +1 (in log scale) which is relative to the normal copy number. To derive a gene-based copy number, let cna be the copy number of segment f; len be the number of genes contained in f; F_g(f) be the set of gained fragments containing gene g; F_l(g) be the set of lost fragments containing g. We calculate:

\[
\text{gain}(g) = \sum_{f \in F_g(f)} \text{cna}(f) / \text{len}(f), \quad \text{where cna}(f) > 0
\]

\[
\text{loss}(g) = \sum_{f \in F_l(g)} \text{cna}(f) / \text{len}(f), \quad \text{where cna}(f) < 0
\]

Then we performed 1-sample t-test to obtain genes significantly associated with CNA gains and CNA losses for each tumor subtype.

Associations between TFs and deregulations: The rank-based enrichment test GORILLA (Eden et al., 2009) was used to compute the enrichment for ESGs near the top of the rank list of genes sorted by deregulation values. We performed such testing for each CNA and DNAme deregulation. For our context and for each subtype, we combine the gain and loss lists and sort genes by the absolute gain or loss value, giving a rank list of all TFs in genome. Tests that involve TFs used ~10000 TFs as background. Otherwise, tests involving ESGs used the whole-genome background (~170000 genes). Q-value procedure (Storey and Tibshirani, 2003) was applied to correct multiple comparisons.

TF-TF and TF-target networks: For each ChiP’d TF identified as associated to a subtype, we use its ChiP-seq experiment to identify its binding sites in the ESGs. We connect an edge from ChiP’d TF to a gene in the ESG set if the gene has a higher-than expected peak prioritization (Supplementary Data S3 and S4). Then we summarized the results per cell line or cell line group and picked the top cell lines (Supplementary Fig. S1) as models of basal and luminal A.

Next, we identified potential subtype-specific transcription factors based on ChiP-seq data and motif and co-expression evidence, as described below. Detailed steps of TF derivations are in Supplementary Methods.

ChiP-seq based evidence: given ESGs in a subtype, we sought ChiP-seq experiments [from ENCODE (Gerstein et al., 2012)] where the sum of binding intensities at the regulatory regions (50 kb ± TSS) of ESGs are significantly higher than binding at random sets of genes. If significance is reached, then ChiP’d TFs are termed regulators of the subtype.

Motif and coexpression based evidence: we performed motif analyses within peaks of ChiP-seq experiments in relevant cell lines to search for any motifs that might be enriched, as described previously (Machanick and Bailey, 2011). We additionally required that the TF identified via this analysis must be coexpressed to the target genes, to be considered as a regulator (as a motif often encompasses a family of TFs).

See Supplementary Figure S1 for a workflow of our analyses.

To reveal associations between identified TFs and CNA or DNAme, we obtained relevant datasets from the breast cancer cohort in TCGA (Cancer and Atlas, 2012) and two other independent datasets, METABRIC and OSLO2 (Curtis et al., 2012; Fleischer et al., 2014).

DNA methylation (DNAme) processing: TCGA array-based DNAme dataset was downloaded from ICGC in nucleotide-resolution methylation frequencies (beta values). We excluded blood-derived normal samples, and metastatic samples from the TCGA list. We used primary tumor samples and also obtained a separate normal breast tissue sample set from TCGA for comparison. To start, nucleotide-resolution beta values per patient sample was summed to gene-level values. Then, to derive subtype-specific hyper- and hypo-methylated genes, for every gene, we compared the distribution of methylation frequency of subtype patient group and that of the healthy group consisting of normal breast tissue samples, by performing 2-sample t-tests with unequal variance with respect to the normal sample group. Genes with P < 0.01 significance are deemed hyper or hypo-methylated respectively.

Copy number alteration (CNA) processing: For CNA (Curtis et al and TCGA), original data consists of copy number for various chromosomal segments detected per patient. Each copy number ranges from -1 to +1 (in log scale) which is relative to the normal copy number. To derive a gene-based copy number, let cna be the copy number of segment f; len be the number of genes contained in f; F_g(f) be the set of gained fragments containing gene g; F_l(g) be the set of lost fragments containing g. We calculate:

\[
\text{gain}(g) = \sum_{f \in F_g(f)} \text{cna}(f) / \text{len}(f), \quad \text{where cna}(f) > 0
\]

\[
\text{loss}(g) = \sum_{f \in F_l(g)} \text{cna}(f) / \text{len}(f), \quad \text{where cna}(f) < 0
\]

Then we performed 1-sample t-test to obtain genes significantly associated with CNA gains and CNA losses for each tumor subtype.

Associations between TFs and deregulations: The rank-based enrichment test GORILLA (Eden et al., 2009) was used to compute the enrichment for ESGs near the top of the rank list of genes sorted by deregulation values. We performed such testing for each CNA and DNAme deregulation. For our context and for each subtype, we combine the gain and loss lists and sort genes by the absolute gain or loss value, giving a rank list of all TFs in genome. Tests that involve TFs used ~10000 TFs as background. Otherwise, tests involving ESGs used the whole-genome background (~170000 genes). Q-value procedure (Storey and Tibshirani, 2003) was applied to correct multiple comparisons.

TF-TF and TF-target networks: For each ChiP’d TF identified as associated to a subtype, we use its ChiP-seq experiment to identify its binding sites in the ESGs. We connect an edge from ChiP’d TF to a gene in the ESG set if the gene has a higher-than expected peak
signal. Iterating this procedure for all ChIP’d TFs results in a TF-target network. TF-TF network results similarly from connecting the ChIP’d TFs to the TF subset of ESGs. For functional enrichment analysis, circled TFs in the network form a seed gene list that was expanded in SEEK, and the top 200 expanded genes were used to determine enriched GO-terms for the TFs.

Comparisons of basal regions with open chromatin data: DNase-seq and ATAC-seq were downloaded from ENCODE portal or GEO for MDA-MB231, human mammary epithelial cells (HMEC), H1 embryonic stem cells, mesenchymal stem cells (MSC), A549 and MCF10a-Er-Src cells. Accession IDs were SRR7225842, ENCSR000EULW, ENCSR731QJ, ENCSR7940FW, ENCSR385SZQ and ENCSR000ENV. ENCODE-provided data were already in narrowPeaks. For MDA-MB231, we processed the data from raw reads by performing alignment (Langmead and Steven, 2012) and peak calling (Zhang et al., 2015) following standard settings. Peak overlap was computed relative to ChIP-seq experiments.

Decomposition of basal ESGs into lineages: We assigned basal ESGs to epithelial, mesenchymal and early developmental stem lineages using two strategies. (1) ChIP-seq of A549, MCF10a-Er-Src and H1-hESC. (2) DNase-seq of H1, MCF and HMEC. In (1) experiments of each line form groups that we used to perform a group-based 2-sample t-test (unequal variance). Groups were epithelial (A549 and MCF10a-Er-Src) and stem (H1-hESC). This determines whether each gene is significantly assigned to epithelial or stem lineage. In (2) we used log fold-change between cell lines as each cell line is just 1 experiment. Hierarchical clustering was performed, and gene clusters that are specific to each epithelial, stem and mesenchymal were chosen. MSC was used to assign the mesenchymal lineage.

The analysis scripts and data are deposited in Bitbucket https://bitbucket.org/qzhu/breast.cancer.tlt.

3 Results and discussion
We inferred regulatory TFs of the subtype-specific extended signature (ESGs) from a combination of sources: (i) ChIP-seq experiments and (ii) motif and coexpression evidence. ChIP-seq measures experimental binding while motif, coexpression evidence are designed to expand the scope of inferable TFs from ENCODE by a search of additional motifs that may be overrepresented in the regulatory regions of ESGs (Section 2). Additionally, TFs pointed to by the motifs must be coexpressed with the subtype genes to be regulators in this study. We first performed a global ChIP-seq prioritization as per subtype’s ESGs (Supplementary Data S3 and S4) and identified relevant cell lines of each subtype (Supplementary Fig. S1).

3.1 Subtype-specific TFs in luminal and basal subtypes

3.1.1 Transcriptional regulators of the luminal A subtype
ChIP-seq based evidence. The unbiased search of ChIP-seq experiments, where the sum of binding intensities at the regulatory regions of the subtype-specific ESGs were significantly higher than binding at random genes, identified the three well-known luminal A-associated TFs: Esr1, Gata3 and Foxa1 (Fig. 1). The ChIP-seq experiments identifying these TFs came from the MCF7 and T47D cell lines (Supplementary Fig. S1a), well-accepted models of luminal A biology, supporting our analysis and suggesting that the set of TF targets were subtype-specific (Fig. 1a). In contrast, Gata3, Esr1 and Foxa1 binding was much less significantly enriched in the binding regions of the basal-like ESGs [e.g. difference in log2(peak) value] were 7, 9 and 16 respectively] (Fig. 1a). Other transcription factors with strong target enrichments in luminal A ESGs, but not with basal-like ESGs, were Znf217, Etf1, Myc, Foxm1, Max and Tead4 (Fig. 1a). Altogether, over 20 of the 40 top ChIP-seq experiments (P < 1 × 10^{-5}) come from MCF7 (Supplementary Data S3), corroborating the fact that MCF7 is the most appropriate model for the physiology of luminal A subtype.

Motif and coexpression based evidence: Next, by going beyond ChIP-seq data, we found additional regulators of the luminal A ESGs using motif analysis (see Section 2). This returned 16 TFs (Supplementary Tables S4 and S5) that included Xbp1 (X-box binding protein), Pgr (progesterone receptor), Ar (androgen receptor), in addition to the known Foxa1, Esr1, Gata3 for which ChIP-seq data were also available. All of these factors had binding motifs in the 50 kb regulatory regions of luminal A ESGs.

3.1.2 Transcriptional regulators of the basal subtype
When the same analysis was performed for the basal extended signature genes, the ChIP-seq data from the ENCODE revealed significant enrichment for TF binding for Cfos, Stat3, Myc (of MCF10a-Er-Src cells, 20 < log2(peak) < 40), Gr, Fosl2, Tcf12, Arf3 (of A549 cells, 15 < log2(peak) < 19) and Tead4, Chd1, Jund, Rbbsp5, Chbp2 and several others (of H1-hESC cells, −log2(peak) > 10) (Fig. 1b), suggesting that these TFs are regulators of the basal subtype. As expected, weak or no enrichment of binding was observed for luminal A ESGs. Additional 23 basal TFs (Supplementary Tables S4 and S5) were identified from expanding the search to include TF motifs and coexpressed TFs in the basal ESGs. These included Bcl11a, Id4, En1, Sox9, for which literature evidence supports their roles in triple-negative breast cancer or as part of the stem cell differentiation program (Adam et al., 2015; Khaled et al., 2015). Among these, the highly relevant basal Foxo1 is a driver of the TGF-beta signaling pathway and participates in crosstalk with Wnt signaling pathway to influence EMT. Overall these results confirm the validity of the inferred TFs.

Intriguingly, two cell lines, A549 and H1-hESC, were identified as associated to the basal subtype in addition to the conventional MCF10a-Er-Src (Supplementary Fig. S1b). This discovery, given the unbiased nature of our analysis, is interesting as A549 is a cell line of basal epithelial origin, while the H1-hESC of stem cell origin. The identification of A549 and H1-hESC as most similar to the basal subtype of breast cancer based on this analysis may be suggestive of a hybrid basal subtype state consistent with the known epithelial and mesenchymal stem cell characteristics of the basal subtype (Sarrío et al., 2008; Wu et al., 2016). Basal specific TFs are found to regulate a large set of basal co-expressed genes, using the TF-TF network described next.

3.1.3 Interaction networks between the TF and their targets in the luminal and basal subtypes
In the next step, we connected the above inferred TFs to the subtype’s ESGs based on the evidence for binding. In doing so, we...
created a directed TF-TF binding network (Fig. 2) through which we analyzed the interactions between these identified TFs and their targets in the subtype-specific extended signature genes (Fig. 2). A directed edge from TF A to TF B in this network means that A binds to B according to ChIP-seq experiment of A in ENCODE database. The ChIP’ed TFs are highlighted in blue, while the TF subset of the subtype’s ESGs (which are targeted by the ChIP’ed TFs. TF target genes (red nodes) are partitioned into groups based on the self- and co-regulatory functions of ESR1, VIM, c-Met oncogene (MET, \( P = 0.0071 \)), FOXQ1 (\( P = 0.0008 \)) which are EMT hallmarks and regulators. We examined a public Zeb1 ChIP-seq sample (GSM2360622) to ask how basal ESGs are targeted by Zeb1, which represses E-cadherin and is a key inducer of EMT. Indeed, basal ESGs are significantly enriched in Zeb1 targets (\( P = 7.67 \times 10^{-29} \)). We hypothesize that the basal subtype contains mixed cell states and populations marked by the distinct expression of lineage-specific genes for multiple lineages. To this end, we decompose basal ESGs (also a mixture of genes) into those belonging to one, or the other cell lineage, or both lineages (epithelial and stem cell) (Supplementary Figs S4 and S5). We focus on a subset of 265 ESGs that have substantial genome-wide TF binding. We used two approaches. First, TF ChIP-seq experiments may divide the basal ESGs based on differential TF binding at these genes in epithelial (A549, MCF10a-Er-Src) and stem cells (H1-hESC). We note that 79, and 95 genes have TF binding uniquely associated with epithelial and embryonic stem cells (Supplementary Figs S4 and S5). Second, the same ESGs were decomposed based on open chromatin peaks in DNase I hypersensitivity sequencing data in HMEC, MSC and H1-hESC cells (Supplementary Fig. S5a). Overlap of the two approaches show 44 embryonic stem, 25 epithelial and 15 mesenchymal genes within the basal ESGs (Supplementary Fig. S5b). These groups participate in specific biological functions according to the GO-term analysis (Supplementary Fig. S5c).

3.1.4 Extended analysis of EMT and stemness in the basal breast cancer
The basal ESGs contain vimentin (VIM, coexpression \( P = 0.0351 \)), c-Met oncogene (MET, \( P = 0.0071 \)), FOXQ1 (\( P = 0.0008 \)) which are EMT hallmarks and regulators. We examined a public Zeb1 ChIP-seq sample (GSM2360622) to ask how basal ESGs are targeted by Zeb1, which represses E-cadherin and is a key inducer of EMT. Indeed, basal ESGs are significantly enriched in Zeb1 targets (\( P = 7.67 \times 10^{-29} \)). We hypothesize that the basal subtype contains mixed cell states and populations marked by the distinct expression of lineage-specific genes for multiple lineages. To this end, we decompose basal ESGs (also a mixture of genes) into those belonging to one, or the other cell lineage, or both lineages (epithelial and stem cell) (Supplementary Figs S4 and S5). We focus on a subset of 265 ESGs that have substantial genome-wide TF binding. We used two approaches. First, TF ChIP-seq experiments may divide the basal ESGs based on differential TF binding at these genes in epithelial (A549, MCF10a-Er-Src) and stem cells (H1-hESC). We note that 79, and 95 genes have TF binding uniquely associated with epithelial and embryonic stem cells (Supplementary Figs S4 and S5). Second, the same ESGs were decomposed based on open chromatin peaks in DNase I hypersensitivity sequencing data in HMEC, MSC and H1-hESC cells (Supplementary Fig. S5a). Overlap of the two approaches show 44 embryonic stem, 25 epithelial and 15 mesenchymal genes within the basal ESGs (Supplementary Fig. S5b). These groups participate in specific biological functions according to the GO-term analysis (Supplementary Fig. S5c).

3.1.5 siRNA, knockout experiments of BCL11A, CTBP2, REST, FOXA1 support the regulation of ESGs
To experimentally verify that these identified TFs indeed regulate ESGs, we obtained public transcriptomic datasets from TF knockout and siRNA conditions for 4 TFs from basal and luminal A regulator lists: BCL11A, CTBP2, REST, and, FOXA1. For each of the luminal A and basal subtypes we found that a greater proportion of subtype-specific genes and subtype-specific TFs are perturbed (i.e. fold-change > 1.5) upon TF knockdown or knockout, when compared to a random set of genes of matched size (Supplementary Fig. S6). Overall this suggests that the regulators identified computationally exert an effect on the subtype-specific target genes also in experimental setting.
Importantly, CpGs located within Foxa1 ChIP-seq peaks near location marks is noted at GATA3, BHLHE40, ZBTB42, SPDEF, TOX3 A/B tumors (Supplementary Fig. S7a). Evidence of hypomethylation, luminal A TFs are characterized by hypomethylation in luminal cancers and epithelial phenotypes. In luminal A cancer, the hypomethylation enhances the commitment of luminal lineage at key lineage-specific markers (GATA3, ER, FOXA1). Moreover, hypomethylation largely extends to the TF binding regions and enhancers of these lineage markers (Fleischer et al., 2017), suggesting a mechanism by which DNAme may control gene expression by interfering with transcription factor binding.

In contrast to luminal A, the TFs driving the basal subtype have remained largely unknown. For this reason there are no ChIP-seq data for ER negative breast cancer cell lines either. Here we report A549, H1-hESC, MCF10a-Er-Src (prioritized from cell lines of 503 ENCODE ChIP-seq) could be used to derive a list of TFs connected in gene regulatory networks in the basal subtype, delineating TFs and their targets and show that they are related to the EMT process and stemness property. The specific TFs and regulatory targets in the basal subtype are first reported here. We have been able to divide these genes as belonging to one of distinct lineages (epithelial, mesenchymal and stem cell) through our network, and summarized TF binding and open chromatin regions.

Applying the combined ChIP-seq/SEEK method also enabled to decompose the heterogeneity among the basal extended signature genes. These genes, otherwise indistinguishable due to their coexpression, have been thanks to the TF binding analysis decomposed into genes belonging to epithelial and to stem cell lineages by the use of A549 and H1-hESC ChIP-seq experiments. A549 and H1-hESC cell lines resemble cell populations in the basal subtype. Of note, H1-hESC is an embryonic cell line. The embryonic stem cell population may be related to the fetal mammary stem cells reported prior (Wahl and Spike, 2017), which are also effectively E-, P- and Her2 low, same as in basal-like breast cancer. Overall, the similarity to these two cell lines shows that there are at least two subpopulations in the basal tumors which are associated with embryonic stemness, epithelial and mesenchymal transition process. Thus, using ENCODE ChIP-seq samples from a diverse panel of cell lines enabled us to postulate unique tumor cell types located within the heterogeneous basal subtype.

### 3.2 Tendencies of TFs to reside in regions affected by CNA and DNAme suggest distinct mechanisms of dysregulations for subtypes

Development of cancer involves dysregulation at multiple levels, including changes to the DNA, such as somatic CNA and aberrant promoter DNAme. We therefore assessed whether in the different breast cancer subtypes the sets of cancer subtype-specific TFs described here, were more often subjected to genetic (CNA) and/or epigenetic (DNAme) aberrations than random sets of TFs. To address this, we used data from 700 breast tumors with subtype-specific DNAme, and CNA data from TCGA and METABRIC. We summarized aberrations on a gene-level to facilitate comparisons with the ESCGs, and tested the relevance of each type of subtype-specific aberration (CNA, DNAme) on the subtype-specific regulators.

#### 3.2.1 Groups of TFs and targets are distinctly associated with subtype-specific breast cancer aberrations including DNAme, CNA

Our results (Table 1) indicate that the groups of subtype-specific TFs identified by our method are more likely perturbed by different cancer aberrations than expected for random TFs. In luminal A tumors, luminal A TFs and their targeted genes are significantly dysregulated by DNAme (see TCGA and Fleischer et al. in Table 1) and to a much less extent by CNA (see TCGA, Curtis et al. in Table 1) (note that Curtis et al. and Fleischer et al. are external cohorts provided in addition to TCGA). In the basal subtype, basal TFs and their targeted genes are dysregulated by CNA (see TCGA, Curtis et al. in Table 2), but not by DNAme (see TCGA, Fleischer et al. in Table 1). Patterns of CNA (Supplementary Fig. S7b) support this observation. The results reflect distinct mechanisms of dysregulation depending on the subtype examined with a distinct pattern of CNA targeting of basal TFs in the basal subpopulation.

Patterns of DNAme dysregulation at the individual TF level are particularly subtype-specific (Supplementary Fig. S7a). For example, we located a subset of TFs containing stem cell differentiation factors SOX9, EN1, GRHL1, FOXC1, ETS2, ETV6 which are hypermethylated in basal tumors and hypermethylated in luminal A tumors (Supplementary Fig. S7b). Such factors in hyper/hypermethylation states possibly suggest that stem-like properties are effectively suppressed in the non-basal subtypes through DNAme. On the other hand, luminal A TFs are characterized by hypomethylation in luminal A/B tumors (Supplementary Fig. S7a). Evidence of hypomethylation marks is noted at GATA3, BHLHE40, ZBTB42, SPDEF, TOX3 in luminal A patients and not in basal (Supplementary Fig. S7a).

Importantly, CpGs located within Foxa1 ChIP-seq peaks near luminal A targets have clear lower methylation than normal and basal groups (Supplementary Fig. S8), suggesting distinct methylation may facilitate the usage of TF binding region in a subtype specific manner. Thus, differential DNAme at TFs plays a critical role in maintaining luminal progenitor states in luminal cancers and epithelial and stem cell states in basal cancers.

### 4 Conclusion

This study demonstrates that each subtype is regulated by a unique repertoire of TFs, and that these subtypes differ by the unique combinations of TFs, switching of binding sites and binding partners. Therefore, forces that deregulate this transcriptional network, through mechanisms of CNA or DNAme of the TFs and their targets, are plausible causes of how subtypes arise. Understanding the interplay between DNAme and CNA will lead to a better understanding of how subtypes arise. The groups of TFs and their targets described here revealed an unexpected tendency to copy number aberrations and DNAme, suggesting that distinctive mechanisms underlie transcriptional regulation. Importantly, luminal A TFs tended toward DNA hypomethylation in luminal cancers while basal TFs tended toward CNA gains/losses in basal cancers. Consistent with the latter finding, basal breast cancer cells accumulate a large number of CNAs, which cause genomic instability (Weigman et al., 2012), and exhibit highly dynamic and complex phenotypes. In luminal A cancer, the hypomethylation enhances the commitment of luminal lineage at key lineage-specific markers (GATA3, ER, FOXA1). Moreover, hypomethylation largely extends to the TF binding regions and enhancers of these lineage markers (Fleischer et al., 2017), suggesting a mechanism by which DNAme may control gene expression by interfering with transcription factor binding.

### Acknowledgements

The authors would like to thank the members of the Troyanskaya, Kristensen laboratories for helpful advice and input. We thank Dr. Anthony Mathelier and Dr. Anthony Hurtado from NCMM for the critical reading of the manuscript.

### Table 1. Significance of accumulation of CNA, DNAme at luminal and basal TFs\(^a\)

| Dataset  | Type  | Basal TFs in basal tumors (Q-val) | Basal targets\(^b\) in basal tumors (Q-val) | LumA TFs in lumA tumors (Q-val) | LumA targets\(^b\) in lumA tumors (Q-val) |
|----------|-------|---------------------------------|---------------------------------|-------------------------------|---------------------------------|
| TCGA     | CNA   | 0.00214                         | 0.00195                         | 0.04                          | 0.023                          |
| Curtis et al. | CNA | 0.00534                         | 0.00018                         | 0.015                         | 0.085                          |
| TCGA     | DNAme| 0.569                           | 0.296                           | 0.022                         | 0.00013                        |
| Fleischer et al. | DNAme | 0.3109                         | 0.0939                         | 0.0153                        | 0.00011                        |

\(^a\)Genes that overlap between ChIP-seq targets, extended signature genes.

\(^b\)Shaded regions indicate consistent patterns of dysregulation across cohorts.
Funding

The work was supported in part by the National Institute of Health (NIH) award R01 HG005998 and partially supported by the National Science Foundation (NSF) CAREER award (DBI-0546273). NIH awards R01 GM071986 and R24OD011194 to O.G.T. O.G.T. is a Senior Fellow of the Canadian Institute For Advanced Research in the Genetic Networks group. X.T has been a fellow of the Norwegian Cancer Society. V.N.K. has been supported by Radiumhospitalets Legater.

Conflict of Interest

ported by Radiumhospitalets Legater.

References

Adam,R.C. et al. (2015) Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. Nature, 521, 366–370.

Aure,M.R. et al. (2013) Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biol., 14, R126.

Cancer,T. and Atlas,G. (2012) Comprehensive molecular portraits of human breast tumours. Nature, 490, 61–70.

Curtis,C. et al. (2012) The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature, 486, 346–352.

Dunham,I. et al. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature, 489, 57–74.

Eden,E. et al. (2009) GO vigil: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics, 10, 48.

Fleischer,T. et al. (2014) Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol., 15, 435.

Fleischer,T. et al. (2017) DNA methylation at enhancers identifies distinct breast cancer lineages. Nat. Commun., 8.

Fullwood,M.J. et al. (2009) An oestrogen-receptor-alpha-bound human chromatin interactome. Nature, 462, 58–64.

Gerstein,M.B. et al. (2012) Architecture of the human regulatory network derived from ENCODE data. Nature, 489, 91–100.

Hu,Z. et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 7, 96.

Hurtado,A. et al. (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet., 43, 27–33.

Janky,R. et al. (2014) iRegulon: from a Gene List to a Gene Regulatory Network Using Large Motif and Track Collections. PLoS Comput. Biol., 10.

Joshi,H. et al. (2012) Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes. BMC Genomics, 13, 199.

Khaled,W.T. et al. (2015) BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. Nat. Commun., 6, 5987.

Kittler,R. et al. (2013) A comprehensive nuclear receptor network for breast cancer cells. Cell Rep., 3, 538–551.

Kundaje,A. et al. (2015) Integrative analysis of 111 reference human epigenomes. Nature, 518, 317–330.

Langmead,B. and Steven,S. (2012) Fast gapped-read alignment with Bowtie 2. Nat. Methods, 9, 357–359.

Machanick,P. and Bailey,T.L. (2011) MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics, 27, 1696–1697.

Muggerud,A.A. et al. (2006) Validation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes. BMC Cancer, 6, 59.

Neph,S. et al. (2012) BEDOPS: high-performance genomic feature operations. Bioinformatics, 28, 1919–1920.

Nik-Zainal,S. et al. (2012) The life history of 21 breast cancers. Cell, 149, 994.

Pellacani,D. et al. (2016) Analysis of normal human mammary epigenomes reveals cell-specific active enhancer states and associated transcription factor networks. Cell Rep., 17, 2060–2074.

Perou,C. et al. (2000) Molecular portraits of human breast tumours. Nature, 406, 747–752.

Sarrió,D. et al. (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res., 68, 989–997.

Sorlie,T. and Perou,C. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA, 98, 10869–10874.

Storey,J.D. and Tibshirani,R. (2003) Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA, 100, 9440–9445.

Tongbai,R. et al. (2008) Transcriptional networks inferred from molecular signatures of breast cancer. Am. J. Pathol., 172, 495–509.

Wahl,G.M. and Spike,R.T. (2017) Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. Nat. Rev. Cancer, 3.

Wei,gman,V.J. et al. (2012) Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res. Treat, 133, 865–880.

Wu,Y. et al. (2016) Epithelial-mesenchymal transition and breast cancer. J. Clin. Med., 5.

Zhang,Y. et al. (2015) Model-based Analysis of ChIP-Seq (MACS), Genome Biol., 9, 1–9.

Zhu,Q. et al. (2015) Targeted exploration and analysis of large cross-platform human transcriptomic compendia. Nat. Methods, 12, 211–214.